PMH12 ECONOMIC CONSEQUENCES OF THE ADVERSE EVENTS RELATED WITH CURRENT ANTIPSYCHOTICS  by Bobes, J et al.
692 Abstracts
OBJECTIVES: The Netherlands Mental Health Survey
and Incidence Study (NEMESIS) is a prospective survey
in the Dutch general population among 7.067 respon-
dents aged 18 to 64. In a follow-up study on the preva-
lence of bipolar disorder (BD) respondents were identiﬁed
by using the Structured Clinical Interview (SCID) result-
ing in a DSM-IV diagnosis for BD. The objective was to
explore the costs to society of BD in the Netherlands. All
available 40 persons identiﬁed with a life-time diagnosis
of BD (DSM-IV) were interviewed. Detailed data on
medical health care utilisation (direct costs) and produc-
tion losses due to absence from work and efﬁciency losses
(indirect costs) as well as quality of life was collected.
METHODS: We used the “Trimbos and iMTA question-
naire on Costs associated with Psychiatric illness (TiC-
P)”. The TiC-P includes a short version of the Health and
Labour questionnaire (HLQ) for collecting data on lost
productivity and efﬁciency losses. For the quality of life
we applied validated generic instruments; the EQ5D of
the EuroQol group and the Short-form 36. RESULTS:
The average direct costs per patient per year was esti-
mated at €897 (range: 0–3200). The average indirect costs
per year was €3720 (range: 0–6373) of which 86% was
due to absence from work. The average score on the
EQ5D was 0.82 (sd 0.2). The quality of life was not sig-
niﬁcantly lower for the BD population compared to the
general population (0.87). Based on the prevalence of
5.2% the total costs of bipolar disorder were estimated
at €1.93 billion (total direct costs = €480 million; total
indirect costs = €1.45 billion). CONLCUSIONS: The
societal costs for bipolar disorder in the Netherlands are
high, especially the indirect costs due to absence from
work. Adequate treatment of bipolar disorder could help
reduce the societal costs and improve patients’ quality of
life.
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OBJECTIVE: To estimate the costs and effects of long-
acting risperidone versus a conventional depot and 
an oral atypical over a 5-year period in Germany.
METHODS: A discrete-event model was developed com-
paring three scenarios. In scenario 1, patients start on
haloperidol depot and may be switched to olanzapine fol-
lowed by clozapine. In scenario 2 patients start on long-
acting risperidone instead of haloperidol depot. In
scenario 3, patients start on olanzapine, and may be
switched to risperidone (oral) followed by clozapine. The
model simulates individual patient histories accounting
for age, gender, type, severity of disease and side effects.
Based on these patient characteristics, the model simu-
lates visits, psychotic episodes, symptom-scores, treat-
ment, compliance and location. Outcomes are expressed
in terms of number and duration of psychotic episodes,
symptom-score and costs. Costs of psychiatrist visits,
medication and location were included. Information was
derived from literature and an expert panel. RESULTS:
Over a 5-year time horizon and per patient, starting with
long-acting risperidone was estimated to avoid 0.21 and
0.32 relapses and to save €131 and €2192 compared to
a conventional depot (scenario 1) and to an oral atypical
(scenario 3) respectively. In subgroup analysis of only
high-risk non-compliant patients starting with long-
acting risperidone was estimated to avoid 0.22 and 0.46
relapses and to save €1442 and €9082. Sensitivity analy-
ses showed that the results are robust and that they are
mainly related to estimates about compliance (when com-
pared to oral atypical agents) and to the effects of atypi-
cal and conventional formulations on the symptom-score.
CONCLUSION: Long-acting risperidone is cost-
effective, as it has higher effectiveness and is cost-neutral
compared to a conventional depot and cost-saving com-
pared to an oral atypical. Further beneﬁts may be
expected, when treatment is aimed at patients with a
high-risk of being non-compliant and at patients in whom
further deterioration is expected.
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OBJECTIVES: Aim of this study was to quantify pro-
duction losses in patients with Borderline Personality Dis-
order (BPD) according to the Human Capital (HC) and
the Friction Costs (FC) methods. METHODS Productiv-
ity levels of BPD-patients were followed for 18 months.
In FC volume was based on the total calendar-period of
absence, irrespective of whether a person was working
part-time or full-time. This is discounted for in the price,
which is based on data from the general working popu-
lation. In FC the price, among other things, also includes
transfer costs. In HC volume was based on actual hours
of absence from work, and price was based on actual pay-
ments. RESULTS: Production losses were €2314 (32 days
¥ €72.31) for FC and €1862 (259 hours ¥ €7.19). CON-
CLUSIONS: Contrary to previous studies, HC results in
lower productivity losses here. Various explanations are
possible. First, in this population, the work pattern is par-
ticularly irregular. The periods of absence are both fre-
quent and short, resulting in repeating friction periods.
Secondly, FC productivity losses are higher when a person
partly resumes work, than when this person remains sick,
which is incorrect from a theoretical point of view. Fur-
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thermore, FC and HC differ in valuation of both volume
and price. Apart from the differences between FC and
HC, neither method takes account of disablement. Many
patients were disabled at the start of the study, and in the
majority of cases, disablement was due to BPD. FC does
not take these costs into account. Although HC is poten-
tially able to value the costs of disablement, this is cur-
rently not the practice in RCTs. However, production
losses associated with disablement are considerable. In
addition, neither FC nor HC provides an answer to the
question what calculations to perform when a person
recovers from disablement and resumes work.
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OBJECTIVES: Frequency of adverse events -AEs- related
with antipsychotics usage is high. Along with clinical
implications, economic impact might be important. A
pharmacoeconomic model has been developed to ascer-
tain the economic impact of patients experiencing these
AEs. The purpose of this study was to model the eco-
nomic consequences of AEs related with current antipsy-
chotics in Spain. METHODS: A cost-effectiveness model
was developed using a Markov modeling approach sim-
ulating treatment of a cohort of schizophrenics for 12
months, initiating treatment with one of four antipsy-
chotic drugs; haloperidol, risperidone, olanzapine and
ziprasidone. The model assumes equivalent efﬁcacy
among the antipsychotics. Conditional probabilities of
developing any of four adverse events was calculated.
Treatment was modiﬁed (decrease dose, switch medica-
tion) according to incidence of AEs and physician judg-
ments, obtained from a local cross-sectional study and
clinical trials previously published. The analysis was con-
ducted in year 2002 from a 3rd party payer perspective
(only direct medical cost are computed). Results are
shown as annual cost per month with psychotic symp-
toms controlled. Univariate sensitivity analysis was per-
formed. RESULTS: The therapeutic strategy starting with
Ziprasidone showed the most favorable cost-effectiveness
ratio, being the dominant option (showing the lower costs
and the greater number of months with symptoms con-
trolled), versus the other options considered. The annual
cost per patient per month with symptoms controlled was
€1.035 with that of ziprasidone, versus €1.084, €1.087,
and €1.090 with haloperidol, risperidone and olanzapine,
respectively. Results are robust to one-way sensitivity
analysis. CONCLUSIONS: Adverse events related with
the usage of antipsychotic drugs produce a considerable
economic impact. Availability of drugs with similar effec-
tiveness but better tolerability than existing agents,
should positively impact on clinic aspects of schizophre-
nia and health care budgets as well.
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OBJECTIVE: Although affective psychoses are usually
associated with adults, it has been reported that at any
given point in time approximately 5% of children and
adolescents in the U.S. general population suffer from
depression. This study sought to identify adolescents
(10–19 years) requiring acute hospital management in
1998 for affective psychoses, their readmissions for these
problems over a 3-year period and the resulting costs.
METHODS: The index admission was identiﬁed in the
1998 Massachusetts all payer hospital database using
ICD-9 diagnosis codes. Suicide attempts were identiﬁed
by E codes. Readmissions were tracked over three years
(1998–2000) by means of a unique patient identiﬁer. All
accommodations, ancillaries and physician services were
included in the cost estimates, which were adjusted for
medical inﬂation, national values, cost-to-charge ratios,
and reported in 2003 US$. RESULTS: A cohort of 890
patients was identiﬁed with 26% coded as bipolar; 12%
admitted due to intentional self-harm. Mean age was 16.4
years (22% = 10–14 years, 78% = 15–19 years); 45%
were male. Index admission mean length of stay was 8.5
days (range: 1–106); 68% spent time in a psychiatric unit.
Mean cost per stay was $7,239 (range: $491–$107,747).
All survived the hospital stay. At discharge, 5% were
transferred to mental health facilities (MHF). Subsequent
to index admission, 25% were readmitted at least once
(mean 1.5, range: 1–11) within 3 years for affective psy-
choses or self-harm and all survived to discharge. The
cumulative 3-year hospital cost for study-relevant admis-
sions for the cohort was estimated at $9.1 million. CON-
CLUSIONS: One quarter of adolescents with affective
psychoses who require acute hospital management can 
be expected to incur additional disorder-related hospital
costs within three years. The estimates, albeit conserva-
tive, as outpatient therapy and MHF care were not
included, illustrate the economic consequences of these
disorders for this age group.
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